Aardvark Therapeutics, Inc. AARD
1.59 USD +0.22 (+16.06%)
At closeNov 11, 2026, 7:10 PM EST
1.58 -0.01 -0.63%
After hours · Nov 11, 7:10 PM ET
1.34 Day range 1.68
0.93 52-week range 16.60
- YTD
- -87.89%
- 1 year
- -85.62%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
benzinga.com HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $4 to $2.
seekingalpha.com Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
benzinga.com Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient Aardvark Therapeutics Inc. (NASDAQ:AARD) stock plunged on Friday after the release of exploratory efficacy data from its terminated Phase 3 HERO trial and open-label extension study.
benzinga.com Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient Aardvark Therapeutics reports Phase 3 data for ARD-101 and prepares to meet with the FDA to discuss lower-dose testing.
benzinga.com Dow Tumbles Over 500 Points; American Express Shares Fall After Q3 Results U.S. stocks fell Friday, led by a 500-point Dow drop. Industrials slid while real estate rose; AmEx fell despite an earnings beat. Oil gained 2%.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
- benzinga.com Aardvark Therapeutics Reports Exploratory Phase 3 HERO And OLE Data Showing Rapid Hunger Score Reductions With ARD-101 In PWS, FDA Lifts Clinical Hold And Company Targets New Phase 3 Trial HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near…
globenewswire.com Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule…
benzinga.com Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
benzinga.com Aardvark Therapeutics Stock Surges as FDA Lifts Clinical Hold After Cardiac Safety Concerns Aardvark Therapeutics shares jumped 25.06% after hours as the FDA lifted its clinical hold on ARD-101 development.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…- benzinga.com FDA Removes Clinical Hold From Aardvark Therapeutics' Investigational New Drug Application For ARD-101 To Treat Hyperphagia In Prader-Willi Syndrome Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the…
globenewswire.com Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial…
zacks.com All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy Aardvark Therapeutics, Inc. (AARD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
benzinga.com HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $6 to $4.
globenewswire.com Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ: AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD)…
globenewswire.com Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and…
newsfilecorp.com AARD DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD New York, New York--(Newsfile Corp. - October 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock…
globenewswire.com SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD A securities class action alleges Aardvark Therapeutics' SEC filings warned about clinical risk in generic terms while describing ARD-101 as "99% restricted to the gut" with "no serious adverse…
globenewswire.com Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New class action for Aardvark (AARD) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/13/2026
businesswire.com CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 NEW YORK--(BUSINESS WIRE)---- $AARD #AARD--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (“Aardvark” or the…
prnewswire.com AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or…
newsfilecorp.com AARD DEADLINE TOMORROW: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD AARD DEADLINE TOMORROW: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD New…
newsfilecorp.com DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their Options If you purchased or…
prnewswire.com AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit SAN FRANCISCO, Oct. 12, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending…
globenewswire.com Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies institutional investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) that a class action lawsuit has been filed on behalf…
gurufocus.com AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 12, 2026LOS ANGELES, Oct.
gurufocus.com Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARDPR NewswireNEW YORK, Oct. 12, 2026NEW YO
prnewswire.com Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD NEW YORK, Oct. 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ: AARD) violations of…
prnewswire.com AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Oct. 12, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark…
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-market session. The company's market cap stands at $213.4 million. China Pharma Holding (AMEX:CPHI) shares…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.
benzinga.com This BWX Technologies Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday Top Wall Street analysts upgraded RXO, BWXT, and Timken stocks with higher price targets. See other analysts' views on these stocks.
benzinga.com This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket Figma Inc (NYSE: FIG) shares rose 10.6% in pre-market trading after beating Q1 revenue and earnings estimates and raising FY26 sales guidance.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-ratings. MDB outlook downgraded to Neutral.
benzinga.com Crude Oil Rises Sharply; Sealed Air Posts Upbeat Earnings Dow Jones down 0.46% amid Iran-U.S. conflict, NASDAQ down 0.22% and S&P 500 down 0.39%. Energy sector up 1.8%, consumer discretionary down 1.7%. Sealed Air Corp beats earnings expectations. The Dow…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Dow Falls 150 Points; ISM Manufacturing PMI Edges Lower In February Stocks fall in US, Dow drops 150 points. Energy sector up, consumer discretionary down. ISM and S&P PMIs decline but beat estimates. Asian markets close lower.
benzinga.com This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Wall Street analysts changed ratings on top stocks. Check out analyst ratings page for full list. NVO downgraded from Buy to Neutral with $41 target.